Neumora Therapeutics (NASDAQ:NMRA) Earns Buy Rating from Guggenheim

Neumora Therapeutics (NASDAQ:NMRA)‘s stock had its “buy” rating reiterated by stock analysts at Guggenheim in a research note issued on Tuesday,Benzinga reports. They presently have a $14.00 price target on the stock.

NMRA has been the subject of a number of other reports. William Blair raised shares of Neumora Therapeutics from a “market perform” rating to an “outperform” rating in a report on Tuesday, February 17th. Mizuho set a $6.00 price objective on shares of Neumora Therapeutics in a report on Monday, January 5th. Leerink Partners initiated coverage on Neumora Therapeutics in a report on Monday, January 12th. They issued an “outperform” rating and a $8.00 price target for the company. Royal Bank Of Canada raised Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and lifted their price objective for the stock from $4.00 to $7.00 in a report on Monday, December 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Neumora Therapeutics in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $7.67.

Neumora Therapeutics Stock Up 7.2%

Shares of NMRA stock opened at $2.09 on Tuesday. Neumora Therapeutics has a 12 month low of $0.61 and a 12 month high of $3.65. The firm has a market cap of $380.46 million, a PE ratio of -1.44 and a beta of 3.08. The stock has a 50 day moving average of $2.74 and a 200-day moving average of $2.32. The company has a quick ratio of 6.85, a current ratio of 6.85 and a debt-to-equity ratio of 0.15.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings data on Monday, March 30th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.01). On average, equities analysts predict that Neumora Therapeutics will post -1.61 EPS for the current year.

Insider Activity

In related news, insider Paul L. Berns sold 9,819 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $3.51, for a total transaction of $34,464.69. Following the completion of the transaction, the insider owned 7,395,185 shares in the company, valued at $25,957,099.35. This trade represents a 0.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last ninety days, insiders sold 23,387 shares of company stock valued at $82,647. Corporate insiders own 26.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Legacy Private Trust Co. bought a new position in shares of Neumora Therapeutics during the third quarter valued at $25,000. Hsbc Holdings PLC acquired a new stake in shares of Neumora Therapeutics during the 4th quarter worth about $27,000. Virtu Financial LLC bought a new position in Neumora Therapeutics during the 3rd quarter valued at about $31,000. Fred Alger Management LLC bought a new position in Neumora Therapeutics during the 4th quarter valued at about $40,000. Finally, Canada Pension Plan Investment Board acquired a new position in Neumora Therapeutics in the second quarter valued at about $41,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.